bGeneral Direction of Disease Control, Ministry of Public Health, Hygiene, and Prevention, Kinshasa, Democratic Republic of the Congo cNational Program of Care and Follow-up of Survivors, Ministry of ...
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in ...
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results